FDA gives the green light to J&J’s bladder cancer therapy.
The US FDA has granted approval for Johnson & Johnson’s drug delivery system aimed at treating bladder cancer, presenting a potential option for those who want to avoid surgery. Known as Inlexzo, this system is intended for patients with non-muscle invasive bladder cancer who haven’t had success with Bacillus Calmette-Guerin (BCG) therapy, which is the […]
FDA Allows Use of J&J’s Ketamine-Derived Nasal Spray Depression Treatment
The U.S. Food and Drug Administration (FDA) has expanded its approval for Johnson & Johnson's nasal spray, Spravato, allowing it to be used as a standalone treatment for millions of U.S. patients dealing with severe depression. The ketamine-derived drug was first approved for use in combination with antidepressants in 2019 and was later used for […]